An inhaled drug developed by the UK firm Synairgen greatly reduces the chances of patients hospitalised with COVID-19 from progressing to more serious stages of the disease.
Press reports suggest that there is good news about AstraZeneca and Oxford University’s COVID-19 vaccine due from an early stage trial in the coming days – but the focus is moving on how to
Coronavirus vaccine trials continue – but experts warn that it’s too early to get hopes up. Meanwhile, the rise in digital health looks like it’s here to stay after the pandemic.
COVID-19 drugs, vaccines and diagnostics that are developed and tested within new international guidelines can expect rapid assessment and authorisation.
The coronavirus pandemic has shrunk timelines for businesses’ adoption of digital technologies to days and weeks from years, with healthcare firms among those implementing the
Medicago has started dosing healthy volunteers in the first human trial of its candidate vaccine for COVID-19, a few days after partnering with GlaxoSmithKline on the project.<